Abstract
Individuals with mild cognitive impairment (MCI) are at increased risk for Dementia of Alzheimers type (DAT), vascular dementia (VaD), Lewy Body (LBD) and Fronto-temporal dementias (FTD). Risk factors and conversion rates of MCI to dementia have not been thoroughly investigated in developing countries. Chinese and English versions of Mini-Mental State Examination were administered serially among well-matched subjects from two clinics located in Xian, China and Houston, USA. Subtle cognitive impairments were weighed according to MCI criteria as defined previously. Subjects with MCI were followed for an additional 3 years after their identification. Diagnoses of VaD and DAT were made according to established criteria. During screening period, 73 American and 65 Chinese individuals were identified with MCI. After 3 years of MCI follow-up, of the 73 American MCI subjects, 35 (47.9%) developed DAT and 15 (20.5%) developed VaD. Of the 65 Chinese MCI subjects, 12 (18.5%) developed DAT and 19 (29.2%) developed VaD. According to Kaplan-Meier analysis, Chinese MCI subjects, despite their lower educational level, are 1.7 times less likely to progress to DAT and 2.3 times more likely to progress to VaD than American subjects within 3 years of MCI being identified (p < 0.01). Data suggest that progression rates of MCI vary considerably among subjects from two countries. American MCI subjects are more prone to DAT, while Chinese subjects are more prone to VaD. Differences in genetic factors, cultures, educational levels, and preventive treatments of vascular risk factors are proposed as responsible for this uneven geographic distribution for different types of dementia.
Keywords: Aging, Alzheimer Disease (DAT), Cross-Cultural Comparison, Vascular Dementia (VAD), Mild Cognitive Impairment (MCI), Psychometrics
Current Alzheimer Research
Title: Cross-Cultural Comparison of Mild Cognitive Impairment between China and USA
Volume: 1 Issue: 1
Author(s): Gelin Xu, John Stirling Meyer, Yuangui Huang, Guanghui Chen, Munir Chowdhury and Minh Quach
Affiliation:
Keywords: Aging, Alzheimer Disease (DAT), Cross-Cultural Comparison, Vascular Dementia (VAD), Mild Cognitive Impairment (MCI), Psychometrics
Abstract: Individuals with mild cognitive impairment (MCI) are at increased risk for Dementia of Alzheimers type (DAT), vascular dementia (VaD), Lewy Body (LBD) and Fronto-temporal dementias (FTD). Risk factors and conversion rates of MCI to dementia have not been thoroughly investigated in developing countries. Chinese and English versions of Mini-Mental State Examination were administered serially among well-matched subjects from two clinics located in Xian, China and Houston, USA. Subtle cognitive impairments were weighed according to MCI criteria as defined previously. Subjects with MCI were followed for an additional 3 years after their identification. Diagnoses of VaD and DAT were made according to established criteria. During screening period, 73 American and 65 Chinese individuals were identified with MCI. After 3 years of MCI follow-up, of the 73 American MCI subjects, 35 (47.9%) developed DAT and 15 (20.5%) developed VaD. Of the 65 Chinese MCI subjects, 12 (18.5%) developed DAT and 19 (29.2%) developed VaD. According to Kaplan-Meier analysis, Chinese MCI subjects, despite their lower educational level, are 1.7 times less likely to progress to DAT and 2.3 times more likely to progress to VaD than American subjects within 3 years of MCI being identified (p < 0.01). Data suggest that progression rates of MCI vary considerably among subjects from two countries. American MCI subjects are more prone to DAT, while Chinese subjects are more prone to VaD. Differences in genetic factors, cultures, educational levels, and preventive treatments of vascular risk factors are proposed as responsible for this uneven geographic distribution for different types of dementia.
Export Options
About this article
Cite this article as:
Xu Gelin, Meyer Stirling John, Huang Yuangui, Chen Guanghui, Chowdhury Munir and Quach Minh, Cross-Cultural Comparison of Mild Cognitive Impairment between China and USA, Current Alzheimer Research 2004; 1 (1) . https://dx.doi.org/10.2174/1567205043480564
DOI https://dx.doi.org/10.2174/1567205043480564 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Metformin: Repurposing Opportunities for Cognitive and Mood Dysfunction
CNS & Neurological Disorders - Drug Targets The Toll-Like Receptor Radical Cycle Pathway: A New Drug Target in Immune-Related Chronic Fatigue
CNS & Neurological Disorders - Drug Targets Blurred Edges: Evolving Concepts of Autism Spectrum Disorders and Schizophrenia
Adolescent Psychiatry Cocaine Dependence and Stroke: Pathogenesis and Management
Current Neurovascular Research Resistin: An Inflammatory Cytokine. Role in Cardiovascular Diseases, Diabetes and the Metabolic Syndrome
Current Pharmaceutical Design Histone Deacetylase Inhibitors and Neurodegenerative Disorders: Holding the Promise
Current Pharmaceutical Design Multifunctional Ligands with Glycogen Synthase Kinase 3 Inhibitory Activity as a New Direction in Drug Research for Alzheimer’s Disease
Current Medicinal Chemistry Targeting of NMDA Receptors in the Treatment of Major Depression
Current Pharmaceutical Design Drug Delivery Systems for Brain Tumor Therapy
Current Pharmaceutical Design Changes in Speech Chunking in Reading Aloud is a Marker of Mild Cognitive Impairment and Mild-to-Moderate Alzheimer’s Disease
Current Alzheimer Research Impaired Neural Transmission and Synaptic Plasticity in Superior Cervical Ganglia from β-Amyloid Rat Model of Alzheimers Disease
Current Alzheimer Research Niacin Status, NAD Distribution and ADP-Ribose Metabolism
Current Pharmaceutical Design NAP Protects against Tau Hyperphosphorylation Through GSK3
Current Pharmaceutical Design The Bioanalytical Molecular Pharmacology of the N-methyl-<sub>D</sub>-Aspartate (NMDA) Receptor Nexus and the Oxygen-Responsive Transcription Factor HIF-1α : Putative Mechanisms and Regulatory Pathways Unravel the Intimate Hypoxia Connection
Current Molecular Pharmacology Phenylbutyric Acid: Simple Structure - Multiple Effects
Current Pharmaceutical Design The Role of Stem Cell Factor and Granulocyte-Colony Stimulating Factor in Treatment of Stroke
Recent Patents on CNS Drug Discovery (Discontinued) AFM-Based Single Molecule Techniques: Unraveling the Amyloid Pathogenic Species
Current Pharmaceutical Design The Development of Topically Acting Carbonic Anhydrase Inhibitors as Antiglaucoma Agents
Current Pharmaceutical Design The Neuroprotective Role of Vesicular Monoamine Transporter 2 in Neurodegenerative Diseases
Medicinal Chemistry Health-Care Associated Pneumonia (HCAP): Identification of Low and High-Risk Patients
Current Respiratory Medicine Reviews